08:00 , Feb 4, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: R-Spondin 1 (RSPO1); RSPO2; RSPO3

Cancer INDICATION: Cancer Patient sample and mouse studies suggest inhibiting RSPO1 , RSPO2 or RSPO3 could help treat cancers. In primary tumor patient samples, RSPO1 was highly expressed in ovarian tumors, RSPO2 was highly expressed...
07:00 , Mar 14, 2013 |  BC Innovations  |  Targets & Mechanisms

Placing kinases in the WNT pathway

Despite the well-established role of WNT signaling in many cancers, the pathway has proven difficult to modulate therapeutically because it is largely composed of hard-to-target protein-protein interactions. Now, a Boston-based team and a group led...
07:00 , Sep 13, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Colorectal cancer R-Spondin 2 (RSPO2); RSPO3 Human genomic studies suggest antagonizing RSPO2 and RSPO3 gene fusion proteins could be useful for treating colorectal cancer. Sequencing...